{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ELVN",
  "name": "Enliven Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/ELVN/",
  "json_url": "https://orbyd.app/dossiers/ELVN.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "June 11 was the last new clinical datapoint; what carried price to $60.46 on 2026-08-07 was the 8/5 Q2 print ($895.2M cash, runway into 2030, Fast Track) plus a same-week target cluster (Stifel $82, GS $80, Guggenheim cut to $78). Funded pivotal-stage story with an agreed ENABLE-2 design — and no dated catalyst inside 30 days, with RSI 76.4 at the highs.",
  "invalidation_trigger": "A weekly close below $48.50 round-trips the August re-rate back through the July post-EHA shelf; confirmed by ENABLE-2 failing to initiate by 2026-12-31 against repeated 2H 2026 guidance.",
  "catalyst_date": null,
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "oncology-immunology"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "Pre-revenue clinical-stage: no product revenue line, so every quarterly print is a spend-and-milestone report rather than a fundamentals check.",
    "ELVN-001 carries effectively the entire valuation; a single safety or regulatory event moves the whole equity, not a segment of it.",
    "Cash, cash equivalents and marketable securities were $895.2M at 2026-06-30 with runway guided into 2030 — near-term financing pressure is low but Phase 3 costs step R&D up.",
    "Weighted-average shares were 66.2M in Q2 2026 vs 52.1M in Q2 2025 after the 2026-06-12 offering of 8,933,334 shares at $37.50 plus pre-funded warrants.",
    "Published target band spans $64–$82 as of 2026-08-06 — the dispersion itself reflects wide model assumptions on 2L+ CML share capture.",
    "Conference-day co-movement with clinical-stage oncology peers means overlapping ASCO/EHA/ASH windows act as one concentrated sector exposure."
  ],
  "body_markdown": "## Current Thesis\nThe June 11 EHA binary is still the last piece of new clinical information in this name, but the story it left behind has hardened into something a fund can underwrite: a single asset with an agreed pivotal design, Fast Track in hand, and enough cash to run the trial without touching the market again. The 2026-08-05 Q2 release put cash, cash equivalents and marketable securities at $895.2M as of 2026-06-30 with runway guided into 2030, and disclosed FDA Fast Track Designation for ELVN-001. The next morning three houses re-marked: Stifel to $82, Goldman Sachs to $80, Guggenheim down to $78. Price followed — the 2026-08-07 close of $60.46 sits 1.1% under the $61.11 52-week high, +48.4% over three months, with RSI(14) at 76.4. What an investor is buying here is the gap between a $37.50 June 12 offering print and a sell-side band of $64–$82 on an asset whose registrational trial has a dose, a population and a comparator but has not yet enrolled a patient. Nothing dated resolves inside the next 30 days.\n\n## Bull Case\n- **The pivotal design is agreed, not aspirational.** The 2026-06-11 release states FDA alignment on 80 mg once-daily as the recommended Phase 3 dose, a population of CML patients previously treated with one or more TKIs, and a comparator of physician's choice ATP-competitive TKI. Design risk on the largest single line item is materially lower than it was in April.\n- **The 80 mg dataset held up when the denominator grew.** Per the same 2026-06-11 release: 61% overall MMR and 48% MMR achievement by 24 weeks in the 80 mg QD cohort (n=21 for the 24-week measure), rising to 67% overall MMR in patients with one to two prior TKIs.\n- **Tolerability is the commercial argument.** 6% discontinuation for adverse events and Grade ≥3 AEs in 24% (15/62) at 80 mg, across 161 enrolled with 35 weeks median treatment duration (2026-06-11). Ponatinib and asciminib each carry cardiovascular or arterial-occlusive baggage.\n- **Fast Track granted.** Disclosed in the 2026-08-05 Q2 business update — review-interaction optionality that did not exist at the time of the June raise.\n- **Financing risk is off the table for the trial's duration.** $895.2M at 2026-06-30 against a Q2 net loss of $32.5M and R&D of $29.0M; management guides runway into 2030.\n- **Coverage is still marking up.** Seven published target actions since 2026-06-29 (Jones $70, Stifel $80 on 7/1, HC Wainwright $64 on 7/9, Goldman $67 on 7/21, then Stifel $82 / Goldman $80 / Guggenheim $78 on 8/6) — every one above the 2026-08-07 close.\n\n## Bear Case\n- **No new clinical information since 2026-06-11.** The August leg to $60.46 was produced by a financial print and three model updates on 8/6, not by a new dataset. The June abstract itself carried previously-reported figures.\n- **The re-rate is largely spent at the target band.** Consensus targets cluster $78–$82 against a $60.46 close; Guggenheim's 8/6 action was a *cut* to $78, the first two-way move in the cluster.\n- **Q2 missed on the line the street models.** EPS of $(0.49) versus a $(0.40) estimate (2026-08-05), driven by R&D stepping to $29.0M from $21.5M a year earlier — and Phase 3 costs have not started.\n- **The comparator answers a narrower question than the pitch implies.** Physician's choice of an ATP-competitive TKI is not asciminib. A win against older TKIs in 2L+ leaves the head-to-head against Scemblix, the drug the wedge argument is built on, unresolved.\n- **Cross-trial framing remains fragile.** The 24-week MMR figure rests on n=21 in the 80 mg cohort. Small denominators against Novartis's controlled 1L data do not settle superiority.\n- **Share count is 27% higher year-over-year.** Weighted-average shares of 66.2M in Q2 2026 versus 52.1M in Q2 2025, reflecting the 8,933,334-share June 12 offering at $37.50 plus pre-funded warrants.\n- **Extension.** RSI(14) at 76.4 into a 52-week high with no dated event for at least seven weeks.\n\n## Setup & Price Structure\n- 2026-08-07 close $60.46; 52-week high $61.11 (-1.1%); three-month return +48.4%; RSI(14) 76.4.\n- The August range was built in two sessions: the 8/5 Q2 print and Fast Track disclosure, then the 8/6 Stifel/Goldman/Guggenheim cluster. That two-day shelf is the newest structure and has not been retested.\n- The $37.50 June 12 offering price — the reference floor in the prior coverage — now sits roughly 38% below the close. It has stopped being a proximate level and become a historical mark.\n- The working structure is the July consolidation high near $48.50 (the post-EHA peak of $48.53 cited when this name was last written up on 2026-07-12), which the August move used as its launch shelf. A weekly close back beneath it would mean the August re-rate round-tripped entirely.\n- **Narrative life-cycle: MATURING.** Still working (new highs on 2026-08-07), well known (seven target actions in six weeks from 2026-06-29 to 2026-08-06), but the information flow has moderated — the last new clinical datapoint is dated 2026-06-11 and the August advance is a re-marking of that same dataset. It is not SATURATED: spot trades below every published target, and the pivotal has not started.\n- **Crowding observables, stated as observables:** RSI(14) 76.4 with price 1.1% off the high; a seven-deep analyst cluster in six weeks with one downward revision inside it; issuance into strength already executed at $37.50 on 2026-06-12; share count +27% YoY. Insider transaction data is not in hand for this period and is not asserted here.\n\n## Catalyst Calendar (next 30 days)\n- **2026-08-08 → 2026-09-07: no company-confirmed dated event.** The Q2 report (2026-08-05) and its 10-Q are behind the tape; the earnings binary for this quarter is closed.\n- **~2026-09-30 (est.)** — End-of-Phase 2 meeting with FDA, guided to Q3 2026 in both the 2026-06-11 and 2026-08-05 releases. Sets the final ENABLE-2 design elements. Date not fixed publicly; may or may not be disclosed contemporaneously.\n- **~2026-11-05 (est.)** — Q3 2026 results. The reporting checkpoint where ENABLE-2 initiation timing either holds at 2H 2026 or slips.\n- **~2026-12-31 (est.)** — ENABLE-2 Phase 3 initiation, per repeated 2H 2026 guidance. This is the structural event the current multiple is discounting.\n- September healthcare-conference season is under way industry-wide; no Enliven appearance is confirmed in the material reviewed, so none is listed as a date.\n\n## What Would Change Our Mind\nThe thing that breaks first is the August shelf. The 8/5–8/6 advance rests on a financial print and three target revisions, with the underlying dataset unchanged since 2026-06-11 — so a full round-trip back through the July consolidation would say the re-rate was flow, and the graded condition for that is a weekly close below $48.50. Beneath that, the 2026-06-12 offering price of $37.50 is where secondary buyers go underwater.\n\nOn the fundamental side, three things would flip the read independently of price:\n- ENABLE-2 not initiating by 2026-12-31, or the Q3 print (~2026-11-05, est.) restating initiation as 1H 2027 — the 2H 2026 guidance has been repeated twice and is the load-bearing timeline.\n- The Q3 2026 End-of-Phase 2 meeting passing without a disclosed outcome, or producing design changes to the agreed 80 mg / 2L+ / physician's-choice-comparator framework.\n- Any Grade ≥3 arterial-occlusive or cardiovascular event emerging as follow-up extends past the 35-week median reported on 2026-06-11. The clean-safety argument is the entire share-capture case; one signal removes it.\n\nA cluster of target *cuts* following the Guggenheim reduction to $78 on 8/6 would be the coverage-side version of the same break.\n\n## Correlation Notes\n- **Novartis (NVS) is the direct competitive input.** ELVN-001's pitch is defined against Scemblix tolerability and against asciminib's ASC4FIRST 1L data. Any next-generation asciminib readout or label expansion that narrows the tolerability gap is a fundamental input to ELVN regardless of ELVN's own newsflow.\n- **Conference-day co-movement with clinical-stage oncology peers.** Prior coverage of this name flagged roughly 0.8 event-day correlation with KYMR, RLAY and CRNX; overlapping ASCO/EHA/ASH windows behave as one concentrated exposure across those names rather than four independent ones.\n- **Rate/XBI beta.** Pre-revenue single-asset biotech carries long-duration sensitivity; a $895.2M balance sheet insulates the funding path but not the multiple during index-level drawdowns.\n- **The asset is now the company.** With no revenue line and one clinical program carrying the valuation, ELVN's idiosyncratic variance dominates its sector beta on any day carrying company-specific news.",
  "first_seen": "2026-04-19",
  "last_analyzed": "2026-08-08T15:13:36+00:00",
  "last_synthesized": "2026-08-08",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}